Cabaletta Bio, Inc.

CABA

Healthcare|Biotechnology|US

$1.30

+0.02 (+1.56%)

DCF Value

$0.49

Tangible Book / Share

$1.52

Cash / Share

$1.60

Clinical Trials (7)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06154252 RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy	Idiopathic Inflammatory Myopathy, Dermatomyositis	P2P3	Recruiting	74	Open-label	CABA-201 following preconditioning with fludarabine and cyclophosphamide
NCT06328777 RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis	Systemic Sclerosis, Scleroderma	P2P3	Recruiting	37	Open-label	CABA-201, CABA-201
NCT06359041 RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis	Generalized Myasthenia Gravis (gMG)	P1P2	Recruiting	24	Open-label	CABA-201, CABA-201
NCT04422912 A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)	Pemphigus Vulgaris	P1P2	Recruiting	40	Open-label	DSG3-CAART, CABA-201
NCT06121297 RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus, Lupus Nephritis	P1P2	Recruiting	28	Open-label	CABA-201, CABA-201
NCT07006805 RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis	Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS)	P1P2	Withdrawn	—	Open-label	CABA-201
NCT05451212 Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis	MuSK Myasthenia Gravis	P1	Completed	7	Open-label	MuSK-CAART